Please assess the completion status of the following clinical trial:

Trial Title: Spectacle Independence and Overall Satisfaction With AcrySof® Panoptix® Toric Intraocular Lens

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~Subjects are eligible for the study if they meet the following criteria:~Note: Ocular criteria must be met in both eyes.~* Presenting for uncomplicated bilateral cataract surgery and have an interest in spectacle independence using a multifocal toric IOL option~* Gender: Males and Females.~* Age: 40 or older.~* Willing and able to provide written informed consent for participation in the study.~* Willing and able to comply with scheduled visits and other study procedures.~* Have good ocular health, with no pathology that compromises visual acuity (outside of residual refractive error and cataract)~* Have regular corneal astigmatism with a magnitude that can be treated with a toric IOL in the approved range (T3-T6) for the Panoptix lens.~* Have 20/32 (0.2 logMAR) or better potential acuity in both eyes~Exclusion Criteria If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.~* Irregular astigmatism (e.g. keratoconus)~* Corneal pathology (e.g. scar, dystrophy, pterygium, moderate-to-severe dry eye)~* Monocular status (e.g. amblyopia)~* Previous radial keratotomy, corneal refractive surgery or other corneal surgery (e.g. corneal transplant, DSAEK, lamellar keratoplasty)~* Previous anterior or posterior chamber surgery (e.g., vitrectomy, laser iridotomy)~* Diabetic retinopathy~* Macular pathology (e.g. ARMD, ERM)~* History of retinal detachment~* Subjects who have an acute or chronic disease or illness that would confound the results of this investigation (e.g., immunocompromised, connective tissue disease, clinically significant atopic disease, diabetes, and any other such disease or illness), that are known to affect postoperative visual acuity.~* Participation in any investigational drug or device trial within the previous 30 days prior to the start date of this trial (or currently participating).~The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.~Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Enrolled subjects (Type: None): Subjects ≥40 years of age presenting for cataract surgery who are interested in reducing their dependence on spectacles at all distances, and who are appropriate candidates for multifocal lens implantation.~The Acrysof (R) Panoptix (R) Toric intraocular lens will be implanted in both eyes of subjects.

Based on this trial design, predict the completion outcome and termination type (if applicable).